title: Clinical prognostic value of metastasis-associated lung adenocarcinoma transcript 1 in various human cancers: an updated meta-analysis.
abstract: BACKGROUND
  Many studies have investigated the prognostic value of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in human cancers. However, these studies were often limited by small sample sizes. Therefore, we performed this updated meta-analysis to summarize the potential value of MALAT1 as a biomarker for early treatment and to predict survival in various human malignant neoplasms, through the inclusion of the latest literature and improved methodology.
  
  
  METHODS
  Twelve eligible articles were systematically obtained from PubMed, Medline, Embase, Web of Science, China National Knowledge Infrastructure and the Cochrane Library, from inception up to June 30, 2015. Survival was assessed using pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs).
  
  
  RESULTS
  By combining the results of 12 studies, we found elevated MALAT1 expression was associated with poor survival in most cancers, with a pooled HR of 1.90 (95% CI, 1.56-2.30) for overall survival (OS) and 3.06 (95% CI, 2.06-4.56) for recurrence-free survival/disease-free survival. Subgroup analyses according to ethnicity, tumor type, assay method, sample size, HR-calculation method and analysis type did not affect the predictive role of MALAT1 for OS in various cancer types. Further, by combining results from studies that used multivariate analyses, we found elevated MALAT1 was an independent prognostic factor for OS (HR = 1.98; 95% CI, 1.58-2.48).
  
  
  CONCLUSIONS
  MALAT1 could serve as a potential prognostic biomarker in various cancers and may be a potential therapeutic target for the treatment and early detection of recurrence.
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Yang
authors: Y
authors: Li
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Ze
authors: Z
authors: Yang
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Xiaoya
authors: X
authors: Wan
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Jianguo
authors: J
authors: Zhou
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Yu
authors: Y
authors: Zhang
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Hu
authors: H
authors: Ma
authors: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi - PR China.
authors: Yuju
authors: Y
authors: Bai
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009362:Neoplasm Metastasis; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C557041:MALAT1 long non-coding RNA, human; D062085:RNA, Long Noncoding